Safety Parameters Sample Clauses
The Safety Parameters clause establishes specific guidelines and requirements to ensure the safety of all parties involved in an agreement or activity. It typically outlines the standards, procedures, and equipment that must be used to minimize risks, such as mandating the use of protective gear or adherence to industry safety protocols. By clearly defining these expectations, the clause helps prevent accidents and injuries, thereby allocating responsibility and reducing liability for safety-related incidents.
Safety Parameters. To avoid inter-observer variability, every effort should be made to ensure that the same individual who made the initial baseline determinations completes all safety assessments. Safety parameters include vital sign measurements, ECG results, physical examination results, adverse events, serious adverse events, weight, and laboratory test results (clinical chemistry, hematology, urinalysis and microscopy).
Safety Parameters. 11.1.1. Demographic
Safety Parameters. The primary safety parameters are the occurrence and severity of adverse events throughout the study treatment period. Refer to §8.2 for AE reporting requirements. The pre-dose assessments performed on Day 1—including PE, ▇▇▇▇▇ ▇▇▇▇▇, and laboratory assessments—will serve as the baseline and the standard for comparison of all follow-up examinations. All abnormal findings will be noted on follow-up and compared to baseline and clinically significant changes will be noted as adverse events.
Safety Parameters. Safety parameters for this study are described in the master protocol. In addition, urine dipstick or urine analysis for protein determination will be performed at Screening and prior to each bevacizumab administration. Patients discovered to have ≥2 proteinuria on dipstick should not be administered bevacizumab, should undergo a 24-hour urine collection, and must demonstrate <2 g of protein in 24 hours to be eligible for bevacizumab treatment to resume.
Safety Parameters. Safety will be assessed by evaluation of adverse events, responses on the C-SSRS and BDI-II, clinical laboratory tests, vital signs, weight, patient ratings of sexual function assessed by the CSFQ-14, and patient-rated assessments of morning sedation as assessed by the MTRSS.
Safety Parameters. 12.1.1. Vital Signs
Safety Parameters. Safety will be assessed by evaluation of AEs; responses on the C-SSRS, and CSFQ-14; clinical laboratory test results, physical examination findings, ECG parameters, vital signs, and weight. AEs associated with abuse liability of the study drug will be evaluated using the MADDERS®. Withdrawal symptoms associated with the study drug after the End of Treatment (Visit 5/ET) will be evaluated using the SOWS.
Safety Parameters. The safety assessments will include adverse events (AEs), BCVA, slit-lamp exam and biomicroscopy, indirect ophthalmoscopy, intraocular pressure (TOP), serum chemistry, hematology, ▇▇▇▇▇ ▇▇▇▇▇, physical exam, fundus photography, fluorescein angiography, EKG, pregnancy.
Safety Parameters. All assessments will be conducted according to the Schedule of Assessments (Table 2).
Safety Parameters